A recent study on high fat diet-fed obese LDLR-/- Leiden mice (presenting obesity-associated hypertriglyceridemia, hypercholesterolemia, hyperglycemia, and hyperinsulinemia) administered with the caspase-1 inhibitor, Ac-YVAD-CMK (40 mg/kg, i.p. once daily), over a period of 12 weeks showed a delayed progression of obesity-associated liver disease and insulin resistance with improved adipose tissue inflammation, but no changes to body weight or dyslipidemia were observed [107]. Here, LDLR is linked to obesity due to melanocortin 4 receptor deficiency.